|
* “Renal involvement in AL amyloidosis: the facts, the promise and the hope”
Pierre Ronco and Pierre Aucouturier
Nephrol Dial Transplant. 2009 Oct;24(10):2967-9.
* “How I treat amyloidosis”
Raymond L. Comenzo
Blood. 2009 Oct 8;114(15):3147-57.
* "Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based stud"
Kristinsson SY, Björkholm M, Andersson TM, Eloranta S, Dickman PW, Goldin LR, Blimark C, Mellqvist UH, Wahlin A, Turesson I, Landgren O.
Haematologica. 2009 Dec;94(12):1714-20.
* Systemic Cardiac Amyloidoses: Disease Profiles and Clinical Courses of the 3 Main Types
Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, Salvi F, Ciliberti P, Pastorelli F, Biagini E, Coccolo F, Cooke RM, Bacchi-Reggiani L, Sangiorgi D, Ferlini A, Cavo M, Zamagni E, Fonte ML, Palladini G, Salinaro F, Musca F, Obici L, Branzi A, Perlini S.
Circulation. 2009 Sep 29;120(13):1203-12.
* Localised primary amyloidosis of the urinary bladder: case series of two patients
Veli Yalcin, Sinharib Citgez, Israfil Agaoglu
BMJ Case Reports 2009; doi:10.1136/bcr.12.2008.1367
* Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study
Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP, Vescio RA, Liu X, Elsayed YA, Cakana A, Comenzo RL; VELCADE CAN2007 Study Group.
Blood. 2009 Aug 20;114(8):1489-97.
|